Source notes
Use drug labels to ask about the medicine, Medicare rules to ask what it may pay, and studies to see how much weight people lost.
Start here to ask what a product is used for and which checks belong in the care plan.
The liraglutide (Saxenda) label describes an injection used once a day.
It calls for the person writing the prescription to review an adult’s weight change after 16 weeks of treatment.
Ask when that review will take place and whether it is in the care fee.
In the SCALE weight study, adults without diabetes were followed for 56 weeks.
Kilograms measure weight, as pounds do. The same weights are shown in pounds below.
People receiving liraglutide lost an average of 8.4 kilograms, or about 18.5 pounds; the placebo group averaged 2.8 kilograms lost, or about 6.2 pounds.
A placebo is a dummy treatment without active medicine. An average describes the group. It does not set a personal target.
Read the comparison: Ask when your weight will be reviewed and whether that visit costs extra.
For type 2 diabetes, liraglutide could be paid for by a Medicare drug plan on September 26, 2026, depending on its list of covered medicines.
Take the product name and reason for care to the plan. Ask for an answer for that prescription.
The liraglutide (Saxenda) list price recorded on September 26, 2026 was a package price, not a quote for care.
Ask separately about the drug, visits, tests, and later check-ins. Keep the amount supplied beside each drug quote.
Read the comparison: Ask the plan about the named product. Ask the care service what its fee includes.
As of September 26, 2026, the maker planned to end liraglutide (Saxenda) shipments to wholesalers in late January 2027.
The maker said the decision was not due to safety or quality concerns.
Approval of a generic does not establish that it is stocked at a pharmacy.
Ask the person writing your prescription what the care plan would be if the medicine is not available.